|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | Novartis AG (NVS), a developer and manufacturer of pharmaceuticals and nutritional products. |
|---|---|
| Transferring Party | Eon Labs, Inc. (Nasdaq:ELAB), a leading U.S. based supplier of generic pharmaceuticals, and Hexal AG ,, #2 generic pharma company in Germany. |
| Sector | Biopharmaceuticals |
| Date | February 21, 2005 |
| Analysis Both deals significantly fortify Novartis as the leading generic drug maker in the world. The Eon deal is valued at over $8.0 billion and the Hexal at about $5.6 billion. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |